Dapagliflozin and New York Heart Association functional class in heart failure with mildly reduced or preserved ejection fraction: the DELIVER trial

被引:38
作者
Ostrominski, John W. [1 ]
Vaduganathan, Muthiah [1 ]
Claggett, Brian L. [1 ]
de Boer, Rudolf A. [2 ]
Desai, Akshay S. [1 ]
Dobreanu, Dan [3 ]
Hernandez, Adrian F. [4 ,5 ]
Inzucchi, Silvio E. [6 ]
Jhund, Pardeep S. [7 ]
Kosiborod, Mikhail [8 ]
Lam, Carolyn S. P. [2 ,9 ,10 ]
Langkilde, Anna M. [11 ]
Lindholm, Daniel [11 ]
Martinez, Felipe A. [12 ]
O'Meara, Eileen [13 ]
Petersson, Magnus [11 ]
Shah, Sanjiv J. [14 ]
Thierer, Jorge [15 ]
McMurray, John J., V [7 ]
Solomon, Scott D. [1 ]
机构
[1] Harvard Med Sch, Brigham & Womens Hosp, Div Cardiovasc, Boston, MA 02115 USA
[2] Univ Groningen, Univ Med Ctr Groningen, Dept Cardiol, Groningen, Netherlands
[3] Univ Med Pharm Sci & Technol GE Palade, Targu Mures, Romania
[4] Duke Univ, Dept Med, Durham, NC USA
[5] Duke Univ, Duke Clin Res Inst, Durham, NC USA
[6] Yale Univ, Sch Med, Sect Endocrinol, New Haven, CT USA
[7] Univ Glasgow, British Heart Fdn, Cardiovasc Res Ctr, Glasgow, Lanark, Scotland
[8] Univ Missouri Kansas City, St Lukes Mid Amer Heart Inst, Kansas City, MI USA
[9] Natl Heart Ctr Singapore, Singapore, Singapore
[10] Duke Natl Univ Singapore, Singapore, Singapore
[11] BioPharmaceut R&D, Late Stage Dev Cardiovasc Renal & Metab, Gothenburg, Sweden
[12] Univ Nacl Cordoba, Cordoba, Argentina
[13] Univ Montreal, Inst Cardiol Montreal, Montreal, PQ, Canada
[14] Northwestern Univ, Feinberg Sch Med, Feinberg Cardiovasc Res Inst, Chicago, IL 60611 USA
[15] Ctr Educ Med & Invest Clin Norberto Quirno CEM, Unidad Insuficiencia Cardiaca, Buenos Aires, DF, Argentina
关键词
Dapagliflozin; Heart failure with preserved ejection fraction; Functional status; New York Heart Association classification; SGLT2; INHIBITORS; MORTALITY; OUTCOMES;
D O I
10.1002/ejhf.2652
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Aims This pre-specified analysis of the DELIVER trial examined whether clinical benefits of dapagliflozin in heart failure (HF) with left ventricular ejection fraction (LVEF) >40% varied by baseline New York Heart Association (NYHA) class and examined the treatment effects on NYHA class over time. Methods and results Treatment effects of dapagliflozin by baseline NYHA class II (n = 4713) versus III/IV (n = 1549) were examined on the primary endpoint (cardiovascular death or worsening HF event) and key secondary endpoints. Effects of dapagliflozin on change in NYHA class at 4, 16, and 32 weeks were also evaluated. Higher baseline NYHA class was associated with older age, female sex, greater comorbidity burden, lower LVEF, and higher natriuretic peptide levels. Participants with baseline NYHA class III/IV, as compared with II, were independently more likely to experience the primary endpoint (adjusted hazard ratio [HR] 1.16 [95% confidence interval, 1.02-1.33]) and all-cause death (adjusted HR 1.22 [1.06-1.40]). Dapagliflozin consistently reduced the risk of the primary endpoint compared with placebo, irrespective of baseline NYHA class (HR 0.81 [0.70-0.94] for NYHA class II vs. HR 0.80 [0.65-0.98] for NYHA class III/IV; p(interaction) = 0.921). Participants with NYHA class III/IV had greater improvement in Kansas City Cardiomyopathy Questionnaire total symptom scores between baseline and 32 weeks (+4.8 [2.5-7.1]) versus NYHA class II (+1.8 [0.7-2.9]; p(interaction) = 0.011). Dapagliflozin was associated with higher odds of any improvement in NYHA class (odds ratio [OR] 1.32 [1.16-1.51]), as well as improvement to NYHA class I (OR 1.43 [1.17-1.75]), versus placebo at 32 weeks, with benefits seen as early as 4 weeks. Conclusions Among symptomatic patients with HF and LVEF >40%, treatment with dapagliflozin provided clinical benefit irrespective of baseline NYHA class and was associated with early and sustained improvements in NYHA class over time.
引用
收藏
页码:1892 / 1901
页数:10
相关论文
共 33 条
[11]   2022 AHA/ACC/HFSA Guideline for the Management of Heart Failure A Report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines [J].
Heidenreich, Paul A. ;
Bozkurt, Biykem ;
Aguilar, David ;
Allen, Larry A. ;
Byun, Joni J. ;
Colvin, Monica M. ;
Deswal, Anita ;
Drazner, Mark H. ;
Dunlay, Shannon M. ;
Evers, Linda R. ;
Fang, James C. ;
Fedson, Savitri E. ;
Fonarow, Gregg C. ;
Hayek, Salim S. ;
Hernandez, Adrian F. ;
Khazanie, Prateeti ;
Kittleson, Michelle M. ;
Lee, Christopher S. ;
Link, Mark S. ;
Milano, Carmelo A. ;
Nnacheta, Lorraine C. ;
Sandhu, Alexander T. ;
Stevenson, Lynne Warner ;
Vardeny, Orly ;
Vest, Amanda R. ;
Yancy, Clyde W. .
JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 2022, 79 (17) :E253-E421
[12]   Mortality associated with heart failure with preserved vs. reduced ejection fraction in a prospective internationalmulti-ethnic cohort study [J].
Lam, Carolyn S. P. ;
Gamble, Greg D. ;
Ling, Lieng H. ;
Sim, David ;
Leong, Kui Toh Gerard ;
Yeo, Poh Shuan Daniel ;
Ong, Hean Yee ;
Jaufeerally, Fazlur ;
Ng, Tze P. ;
Cameron, Vicky A. ;
Poppe, Katrina ;
Lund, Mayanna ;
Devlin, Gerry ;
Troughton, Richard ;
Richards, A. Mark ;
Doughty, Robert N. .
EUROPEAN HEART JOURNAL, 2018, 39 (20) :1770-1780
[13]   Semiparametric regression for the mean and rate functions of recurrent events [J].
Lin, DY ;
Wei, LJ ;
Yang, I ;
Ying, Z .
JOURNAL OF THE ROYAL STATISTICAL SOCIETY SERIES B-STATISTICAL METHODOLOGY, 2000, 62 :711-730
[14]   Mechanisms of Cardiovascular Benefits of Sodium Glucose Co-Transporter 2 (SGLT2) Inhibitors A State-of-the-Art Review [J].
Lopaschuk, Gary D. ;
Verma, Subodh .
JACC-BASIC TO TRANSLATIONAL SCIENCE, 2020, 5 (06) :632-644
[15]   Relationship between changing patient-reported outcomes and subsequent clinical events in patients with chronic heart failure: insights from HF-ACTION [J].
Luo, Nancy ;
O'Connor, Christopher M. ;
Cooper, Lauren B. ;
Sun, Jie-Lena ;
Coles, Adrian ;
Reed, Shelby D. ;
Whellan, David J. ;
Pina, Ileana L. ;
Kraus, William E. ;
Mentz, Robert J. .
EUROPEAN JOURNAL OF HEART FAILURE, 2019, 21 (01) :63-70
[16]   CHRONIC CONGESTIVE-HEART-FAILURE - DESCRIPTION AND SURVIVAL OF 190 CONSECUTIVE PATIENTS WITH A DIAGNOSIS OF CHRONIC CONGESTIVE-HEART-FAILURE BASED ON CLINICAL SIGNS AND SYMPTOMS [J].
MADSEN, BK ;
HANSEN, JF ;
STOKHOLM, KH ;
BRONS, J ;
HUSUM, D ;
MORTENSEN, LS .
EUROPEAN HEART JOURNAL, 1994, 15 (03) :303-310
[17]   2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure [J].
McDonagh, Theresa A. ;
Metra, Marco ;
Adamo, Marianna ;
Gardner, Roy S. ;
Baumbach, Andreas ;
Boehm, Michael ;
Burri, Haran ;
Butler, Javed ;
Celutkiene, Jelena ;
Chioncel, Ovidiu ;
Cleland, John G. F. ;
Coats, Andrew J. S. ;
Crespo-Leiro, Maria G. ;
Farmakis, Dimitrios ;
Gilard, Martine ;
Heymans, Stephane ;
Hoes, Arno W. ;
Jaarsma, Tiny ;
Jankowska, Ewa A. ;
Lainscak, Mitja ;
Lam, Carolyn S. P. ;
Lyon, Alexander R. ;
McMurray, John J., V ;
Mebazaa, Alexandre ;
Mindham, Richard ;
Muneretto, Claudio ;
Piepoli, Massimo Francesco ;
Price, Susanna ;
Rosano, Giuseppe M. C. ;
Ruschitzka, Frank ;
Skibelund, Anne Kathrine .
EUROPEAN HEART JOURNAL, 2021, 42 (36) :3599-3726
[18]   Dapagliflozin in Patients with Heart Failure and Reduced Ejection Fraction [J].
McMurray, J. J. V. ;
Solomon, S. D. ;
Inzucchi, S. E. ;
Kober, L. ;
Kosiborod, M. N. ;
Martinez, F. A. ;
Ponikowski, P. ;
Sabatine, M. S. ;
Anand, I. S. ;
Belohlavek, J. ;
Bohm, M. ;
Chiang, C. -E. ;
Chopra, V. K. ;
de Boer, R. A. ;
Desai, A. S. ;
Diez, M. ;
Drozdz, J. ;
Dukat, A. ;
Ge, J. ;
Howlett, J. G. ;
Katova, T. ;
Kitakaze, M. ;
Ljungman, C. E. A. ;
Merkely, B. ;
Nicolau, J. C. ;
O'Meara, E. ;
Petrie, M. C. ;
Vinh, P. N. ;
Schou, M. ;
Tereshchenko, S. ;
Verma, S. ;
Held, C. ;
DeMets, D. L. ;
Docherty, K. F. ;
Jhund, P. S. ;
Bengtsson, O. ;
Sjostrand, M. ;
Langkilde, A. -M. .
NEW ENGLAND JOURNAL OF MEDICINE, 2019, 381 (21) :1995-2008
[19]   The SGLT2 inhibitor dapagliflozin in heart failure with preserved ejection fraction: a multicenter randomized trial [J].
Nassif, Michael E. ;
Windsor, Sheryl L. ;
Borlaug, Barry A. ;
Kitzman, Dalane W. ;
Shah, Sanjiv J. ;
Tang, Fengming ;
Khariton, Yevgeniy ;
Malik, Ali O. ;
Khumri, Taiyeb ;
Umpierrez, Guillermo ;
Lamba, Sumant ;
Sharma, Kavita ;
Khan, Sadiya S. ;
Chandra, Lokesh ;
Gordon, Robert A. ;
Ryan, John J. ;
Chaudhry, Sunit-Preet ;
Joseph, Susan M. ;
Chow, Chen H. ;
Kanwar, Manreet K. ;
Pursley, Michael ;
Siraj, Elias S. ;
Lewis, Gregory D. ;
Clemson, Barry S. ;
Fong, Michael ;
Kosiborod, Mikhail N. .
NATURE MEDICINE, 2021, 27 (11) :1954-+
[20]   Effect of Empagliflozin on Worsening Heart Failure Events in Patients With Heart Failure and Preserved Ejection Fraction EMPEROR-Preserved Trial [J].
Packer, Milton ;
Butler, Javed ;
Zannad, Faiez ;
Filippatos, Gerasimos ;
Ferreira, Joao Pedro ;
Pocock, Stuart J. ;
Carson, Peter ;
Anand, Inder ;
Doehner, Wolfram ;
Haass, Markus ;
Komajda, Michel ;
Miller, Alan ;
Pehrson, Steen ;
Teerlink, John R. ;
Schnaidt, Sven ;
Zeller, Cordula ;
Schnee, Janet M. ;
Anker, Stefan D. .
CIRCULATION, 2021, 144 (16) :1284-1294